IPO

A new space-focused SPAC has launched, but will it reach orbit in a market demanding experienced pilots and proven flight plans over speculative fuel?

A New Zealand tech firm’s public debut isn't just about mowers. It’s a strategic play for a future where robotics and solar power untether us from the grid.

MDB Capital celebrates a string of successful IPOs but reports a staggering $16.1M loss, putting its unique 'public venture' model under intense scrutiny.

A San Diego biotech is advancing a device to clean the blood of disease-fueling particles. With early promise in cancer and a new path in Long COVID, can it navigate the financial realities of innovation?

Curis secures a crucial, albeit small, $5.6M funding lifeline. Will it be enough to push its promising cancer drug through trials before the clock runs out?

With a blockbuster IPO and dazzling growth, Bending Spoons looks unstoppable. But a closer look reveals a high-stakes strategy built on massive debt.

As Standard Nuclear preps its first earnings call post-IPO, the real story is its pivotal role in a new industrial revolution powered by advanced nuclear fuel.

Liftoff Mobile reported a net loss, but a look past the IPO-related accounting reveals a company firing on all cylinders, with its AI platform driving record revenue.

Beyond a 23% profit surge, ILCO's latest results reveal a blueprint for resilience through strategic IPOs, dividends, and a diversified portfolio.

With a cash runway into 2029, Avalyn Pharma is advancing a novel inhaled drug platform, hitting key clinical milestones to challenge an oral-dominated market.

With breakthrough dialysis data and a new heart-mending vessel, Humacyte is balancing radical innovation with commercial reality. Is this the future of medicine?

A biotech's new funding offers a glimmer of hope for a novel cancer therapy, but a look at the books reveals a desperate race against time and capital.

AGT Food and Ingredients' Q2 results signal a successful shift to higher-margin foods, with its packaged foods segment surging despite global headwinds.

Braveheart Bio's stunning IPO debut raised nearly half a billion dollars. We dig into the story behind the numbers and what it signals for the 2026 economy.

The new blank check company debuts with a $100M war chest. A deep dive into its leadership, complex structure, and what its launch means for investors.

iSpecimen's new $5M offering aims to fix its balance sheet and fund expansion. But in a tough market, is this a strategic reset or a temporary patch?

With a fresh $100M, Red Violet isn't just raising capital; it's signaling a major push for acquisitions and innovation in the identity intelligence space.

RECONOVA's massively oversubscribed IPO met a cool reception on its first day, signaling a new era where AI firms must prove profitability, not just potential.

Fresh off its IPO, National Healthcare Properties reports soaring senior housing profits, a dramatic balance sheet overhaul, and a $400M acquisition spree.

Celestica is raising $3 billion to fuel the AI revolution. Is this a masterstroke in building the digital future or a high-stakes gamble for investors?